Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
73.3 ^USD	+2.32%		+6.62%	-9.52%

07-17	Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	MT
07-17	Gilead Sciences Chief Medical Officer to Step Down	DJ

EnvisionRx and Gilead Sciences Inc. Sign Exclusive Agreement to Help in the Fight Against Hepatitis C

January 26, 2015 at 01:00 pm

EnvisionRx announced a partnership with Gilead Sciences Inc. to provide availability to HCV infection treatments Sovaldi® and Harvoni for EnvisionRx patients on an exclusive basis.

Latest news about Gilead Sciences, Inc.

Gilead Sciences Chief Medical Officer Merdad Parsey to Leave	07-17	MT
Gilead Sciences Chief Medical Officer to Step Down	07-17	DJ
Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025	07-17	CI
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating	07-16	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78	07-11	MT
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating	07-09	MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93	07-08	MT
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	07-01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	07-01	CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	06-26	CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117	06-26	MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	06-25	CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80	06-24	MT
Tech overload on Wall Street	06-21
Wall Street set for muted open as investors await business survey data	06-21	RE
Nvidia Slide Stifles US Equity Futures Pre-Bell	06-21	MT
Top Premarket Gainers	06-21	MT
Wall Street futures edge lower ahead of business survey data	06-21	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	06-20	MT
Equity Markets Close Mixed After Macro Data	06-20	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	06-20	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	06-20	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-20	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	06-20	MT
Equity Markets Mixed as Traders Weigh Macro Data	06-20	MT

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Gilead Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

73.3 USD

Average target price

83.01 USD

Spread / Average Target

+13.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GILEAD SCIENCES, INC.	-9.52%	91.32B
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.09%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ROCHE HOLDING AG	+13.05%	250B
ASTRAZENECA PLC	+16.32%	247B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B

Other Pharmaceuticals

Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

EnvisionRx and Gilead Sciences Inc. Sign Exclusive Agreement to Help in the Fight Against Hepatitis C

Latest news about Gilead Sciences, Inc.

Chart Gilead Sciences, Inc.

Company Profile

Income Statement Evolution

Ratings for Gilead Sciences, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals